|
1
|
Go RS and Wester SM: Immunophenotypic and
molecular features, clinical outcomes, treatments, and prognostic
factors associated with subcutaneous panniculitis-like T-cell
lymphoma: A systematic analysis of 156 patients reported in the
literature. Cancer. 101:1404–1413. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Willemze R, Jansen PM, Cerroni L, Berti E,
Santucci M, Assaf C, Canninga-van Dijk MR, Carlotti A, Geerts ML,
Hahtola S, et al: Subcutaneous panniculitis-like T-cell lymphoma:
Definition, classification and prognostic factors: An EORTC
cutaneous lymphoma group study of 83 cases. Blood. 111:838–845.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parveen Z and Thompson K: Subcutaneous
panniculitis-like T-cell lymphoma: redefinition of diagnostic
criteria in the recent World Health Organization-European
Organization for Research and Treatment of Cancer classification
for cutaneous lymphomas. Arch Pathol Lab Med. 133:303–308.
2009.PubMed/NCBI
|
|
4
|
van Besien K, Ha CS, Murphy S, McLaughlin
P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F,
Younes A, et al: Risk factors, treatment, and outcome of central
nervous system recurrence in adults with intermediate-grade and
immunoblastic lymphoma. Blood. 91:1178–1184. 1998.PubMed/NCBI
|
|
5
|
MacKintosh FR, Colby TV, Podolsky WJ,
Burke JS, Hoppe RT, Rosenfelt FP, Rosenberg SA and Kaplan HS:
Central nervous system involvement in non-Hodgkin's lymphoma: An
analysis of 105 cases. Cancer. 49:586–595. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Colocci N, Glantz M and Recht L:
Prevention and treatment of central nervous system involvement by
non-Hodgkin's lymphoma: A review of the literature. Semin Neurol.
24:395–404. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Willemze R, Jaffe ES, Burg G, Cerroni L,
Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL,
Duncan LM, et al: WHO-EORTC classification for cutaneous lymphomas.
Blood. 105:3768–3785. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim YH, Willemze R, Pimpinelli N,
Whittaker S, Olsen EA, Ranki A, Dummer R and Hoppe RT: ISCL and the
EORTC: TNM classification system for primary cutaneous lymphomas
other than mycosis fungoides and Sezary syndrome: A proposal of the
international society for cutaneous lymphomas (ISCL) and the
cutaneous lymphoma task force of the European organization of
research and treatment of cancer (EORTC). Blood. 110:479–484. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bernstein SH, Unger JM, Leblanc M,
Friedberg J, Miller TP and Fisher RI: Natural history of CNS
relapse in patients with aggressive non-Hodgkin's lymphoma: A
20-year follow-up analysis of SWOG 8516 - the Southwest Oncology
Group. J Clin Oncol. 27:114–119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hollender A, Kvaloy S, Lote K, Nome O and
Holte H: Prognostic factors in 140 adult patients with
non-Hodgkin's lymphoma with systemic central nervous system (CNS)
involvement. A single centre analysis. Eur J Cancer. 36:1762–1768.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rubenstein JL, Gupta NK, Mannis GN,
Lamarre AK and Treseler P: How I treat CNS lymphomas. Blood.
122:2318–2330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kasenda B, Schorb E, Fritsch K, Finke J
and Illerhaus G: Prognosis after high-dose chemotherapy followed by
autologous stem-cell transplantation as first-line treatment in
primary CNS lymphoma - a long-term follow-up study. Ann Oncol.
26:608–611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Omuro A, Correa DD, DeAngelis LM,
Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C,
Pentsova E, Grommes CC, et al: R-MPV followed by high-dose
chemotherapy with TBC and autologous stem-cell transplant for newly
diagnosed primary CNS lymphoma. Blood. 125:1403–1410. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen YB, Batchelor T, Li S, Hochberg E,
Brezina M, Jones S, Del Rio C, Curtis M, Ballen KK, Barnes J, et
al: Phase 2 trial of high-dose rituximab with high-dose cytarabine
mobilization therapy and high-dose thiotepa, busulfan, and
cyclophosphamide autologous stem cell transplantation in patients
with central nervous system involvement by non-Hodgkin lymphoma.
Cancer. 121:226–233. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu JJ, Wang XH, Li L, Li X, Zhang L, Sun
ZC, Fu XR, Ma W, Chang Y, Zhang XD, et al: Fotemustine, teniposide
and dexamethasone in treating patients with CNS lymphoma. Asian Pac
J Cancer Prev. 15:4733–4738. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vassal G, Boland I, Terrier-Lacombe MJ,
Watson AJ, Margison GP, Venuat AM, Morizet J, Parker F, Lacroix C,
Lellouch-Tubiana A, et al: Activity of fotemustine in
medulloblastoma and malignant glioma xenografts in relation to
O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA
N-glycosylase activity. Clin Cancer Res. 4:463–468. 1998.PubMed/NCBI
|
|
17
|
Muggia FM: Teniposide: Overview of its
therapeutic potential in adult cancers. Cancer Chemother Pharmacol.
34(Suppl): S127–S133. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Inaba H and Pui CH: Glucocorticoid use in
acute lymphoblastic leukaemia. Lancet Oncol. 11:1096–1106. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Deng L, Song Y, Zhu J, Zheng W, Wang X,
Xie Y, Lin N, Tu M, Ping L, Ying Z, et al: Secondary central
nervous system involvement in 599 patients with diffuse large
B-cell lymphoma: Are there any changes in the rituximab era? Int J
Hematol. 98:664–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
